FindTrial
Sign In

Effect of oral iron supplementation on glucose tolerance in individuals with anemia

Effect of oral iron supplementation on glucose tolerance in individuals with anemia - NIL

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/09/095345
Enrollment
30
Registered
2025-09-24
Start date
Unknown
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D509- Iron deficiency anemia, unspecified

Interventions

Intervention1: Nil: Nil Intervention2: Oral Iron Supplements (Ferrous Fumarate): Ferrous Fumarate given to treat anemia for a duration of one month. This is the standard treatment of choice

Sponsors

Indian Council of Medical Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients aged 20-49 years and are diagnosed with anemia (Hb less than 12 g/dL) will be recruited to the cohort.

Exclusion criteria

Exclusion criteria: Patients with diabetes, prediabetes, liver, kidney, and inflammatory disorders, and those who are already on iron supplements (for the preceding 4 weeks) will be excluded.

Design outcomes

Primary

MeasureTime frame
Oral iron supplementation given to treat anemia causes impairment of glucose induced insulin secretionTimepoint: 0 days, 30 days—

Secondary

MeasureTime frame
Anemia increases absorption of oral iron leading to excess circulating non-transferrin bound iron (NTBI) This will be taken up by the pancreatic beta cell islets by increased expression of ZIP14 & causes impairment of insulin secretion.Timepoint: 0 days, 30 days—

Countries

India

Contacts

Public ContactJagadish Ramasamy

All India Institute of Medical Sciences

iamjagankmr@gmail.com8015597917

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026